Physician profile
Mitch M Freeman
NPI 1164459434
$1,858.20
in general payments reported to CMS, 2019-2025
12 companies · $66.61 in 2025
The $66.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $515 · 2021: $80.96 · 2022: $170 · 2023: $184 · 2024: $170 · 2025: $66.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Education: $1.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.14 |
| Education | $1.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $981.55 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $253.68 | 2019 | |
| Abbott Laboratories | $186.68 | 2022-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $182.41 | 2023 | Korlym |
| Allergan, INC. | $109.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.39 | 2025 | |
| Glaxosmithkline, LLC. | $27.38 | 2020-2021 | |
| Lilly USA, LLC | $26.03 | 2020-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $22.59 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.65 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.98 | 2020 | |
| Travere Therapeutics, INC. | $1.18 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitch Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.